It is widely accepted that the inflammatory mediator PAF and its receptor are implicated in malignant processes such as tumor development, growth and metastatic angiogenesis. PAF seems to be a significant junction point of several pathways induced by angiogenic factors (such as cytokines and growth factors) in both endothelial and cancer cells. Furthermore PAF has the potential to trigger and enhance such processes by inducing its production, enhancing receptor expression and via angiogenic factors. PAF-receptor specific antagonists have in vitro and in vivo exhibited promising results in several cancer models. Several antioxidants with anti-PAF activity exhibit similar effects. In addition, reduced PAF-biosynthesis and induced degradation by such factors may provide an alternative nontoxic approach to anti-cancer therapy.
Drug targets for cancer: PAF research reagents
Other vital drug targets for cancer likePAF:
Tsoupras A B, et al. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants[J]. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 2009, 9(4): 390-399.